Fig. 5From: Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysisFunnel plot of HER2-low breast cancer vs. HER2-zero breast cancer. OR for the pCR rate: overall cohort (a), HR-positive group(b), HR-negative group(c); HR for OS: overall cohort (d), HR-positive group(e), HR-negative group(f); HR for DFS: overall cohort (g), HR-positive group(h), HR-negative group(i)Back to article page